BCL-2 (2C4) Monoclonal Antibody

Jurkat cell lysate probed with BCL-2 (2C4) Monoclonal Antibody, Unconjugated (bsm-52022M) at 1:1000 overnight at 4˚C. Followed by a conjugated secondary antibody.

$Paraformaldehyde-fixed, paraffin embedded human breast cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal serum) at 37\u00b0C for 20min; Antibody incubation with BCL-2 (2C4) Monoclonal Antibody (bsm-52022M) at 1:50 overnight at 4\u00b0C, followed by a conjugated secondary and DAB staining.$

Paraformaldehyde-fixed, paraffin embedded human breast cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal serum) at 37\u00b0C for 20min; Antibody incubation with BCL-2 (2C4) Monoclonal Antibody (bsm-52022M) at 1:50 overnight at 4\u00b0C, followed by a conjugated secondary and DAB staining.

Applications

WB
IHC-P
IF(ICC)

Reactivity

Human
Mouse

Overview
Catalog #	bsm-52022M
Product Name	BCL-2 (2C4) Monoclonal Antibody
Applications	WB, IHC-P, IF(ICC)
Reactivity	Human, Mouse
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	Recombinant human BCL-2 protein, around 50-150aa.
Clonality	Monoclonal
Clone #	2C4
Isotype	IgG2b
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	596
Swiss Prot	P10415
Synonyms	Apoptosis regulator Bcl-2; BCL2
Background	Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(ICC)	1:50-200